Oyster Mushrooms and Blood Sugar — What the Published Clinical Research Shows

Educational content: This article summarizes peer-reviewed scientific research. These statements have not been evaluated by the Food and Drug Administration. Oyster mushrooms are a food — they are not intended to diagnose, treat, cure, or prevent any disease or medical condition. Consult your physician before making dietary changes, particularly if you manage blood sugar, diabetes, or take prescription medications.

Eight human clinical trials have examined the effect of Pleurotus ostreatus intake on blood glucose parameters. Across all eight, researchers observed beneficial effects on glucose metabolism, including reductions in fasting blood glucose, postprandial glucose, and — in studies involving patients with type 2 diabetes — improvements in glycemic control over sustained intake periods. A 2020 systematic review published in Nutrients concluded that P. ostreatus may improve glucose and lipid metabolism, while noting that the current evidence base requires further large-scale trials with rigorous methodology before definitive conclusions can be drawn.

On this page

• What the systematic review of clinical trials found

• The beta-glucan mechanism

• Clinical trials in patients with type 2 diabetes

• The GLP-1 connection

• What the evidence does and does not show

What the systematic review of clinical trials found

A 2020 systematic review published in Nutrients examined eight human intervention studies that evaluated the effect of Pleurotus ostreatus intake on cardiometabolic parameters. The review applied PRISMA guidelines and the Cochrane Collaboration's tool to assess risk of bias across included studies. All eight trials reported beneficial effects on glucose metabolism — specifically, reductions in fasting plasma glucose (FPG) and/or 2-hour postprandial glucose. Concurrent improvements in lipid profiles were observed in several studies, including reductions in total cholesterol, LDL cholesterol, and triglycerides.

Among the specific findings reported across the eight trials: in healthy subjects consuming a mushroom suspension daily for 14 days, fasting plasma glucose was reduced by 6% compared to baseline. In a subsequent experiment with the same cohort, the glucose concentration in plasma two hours after an oral glucose tolerance test was 16% lower following mushroom intake compared to water, reflecting the combined effect of chronic and acute consumption. A further substudy involving patients with diabetes found that a single preload of mushroom suspension ingested 30 minutes before a glucose challenge produced a measurable reduction in postprandial glucose response compared to water preload.

A systematic review of eight human clinical trials on Pleurotus ostreatus intake found beneficial effects on glucose metabolism in all eight studies, including reductions in fasting and/or 2-hour postprandial glucose and improvements in lipid parameters. The authors concluded that P. ostreatus intake may improve cardiometabolic health, while noting that risk of bias was high or unclear in most studies and that further rigorously designed trials are warranted. Ellinger and Stehle, Nutrients, 2020.

The beta-glucan mechanism

The proposed biological mechanism behind the glucose-related findings centers on beta-glucans — soluble dietary fibers that constitute a significant fraction of oyster mushroom dry weight. Beta-glucans slow gastric emptying and the rate at which glucose is absorbed from the small intestine, blunting the postprandial glucose spike that follows carbohydrate intake. This is a well-characterized mechanism: beta-glucans from oats and barley are recognized by regulatory authorities in multiple countries for their contribution to glycemic management, and the beta-glucans in oyster mushrooms operate through the same physical and enzymatic pathways.

Preclinical research has identified additional mechanisms beyond viscosity-mediated glucose absorption. Studies in animal models have shown that oyster mushroom compounds activate AMPK (adenosine monophosphate-activated protein kinase), a cellular energy sensor that, when activated, promotes glucose uptake by increasing the expression of GLUT4 transporters in muscle tissue — the primary pathway through which insulin-independent glucose clearance occurs. Alpha-glucosidase inhibition, a mechanism shared by several pharmaceutical diabetes medications, has also been documented in oyster mushroom extracts, suggesting multiple convergent pathways through which glucose metabolism may be influenced.

Oyster mushroom compounds have been shown to function as anti-hyperglycemics through phosphorylation of AMPK and increased expression of GLUT4 in type 2 diabetic model rats, identifying a molecular pathway for insulin-independent glucose uptake as a component of the observed hypoglycemic activity. Asrafuzzaman et al., 2018, as reviewed in Agunloye et al., Food Frontiers, 2022.

Clinical trials in patients with type 2 diabetes

A clinical investigation conducted at BIRDEM Hospital in Bangladesh enrolled 89 subjects with type 2 diabetes over a 360-day study period. Participants consuming oyster mushrooms showed significant reductions in fasting plasma glucose, 2-hour postprandial glucose, total cholesterol, triglycerides, and blood pressure compared to baseline. The authors reported no detrimental effects on liver or kidney function across the study period, suggesting an acceptable safety profile at the doses consumed. This remains one of the longest-duration human studies on oyster mushroom consumption and glycemic outcomes published in the literature.

A separate clinical trial published in Phytotherapy Research in 2015 examined the hypoglycemic activity of Pleurotus ostreatus and P. cystidiosus in healthy volunteers and in patients with type 2 diabetes being managed through diet control rather than medication. The study found measurable reductions in fasting blood glucose in both the healthy and diabetic groups following mushroom consumption, and proposed multiple mechanisms of action including alpha-glucosidase inhibition and insulin sensitization.

A 360-day clinical investigation in 89 patients with type 2 diabetes found that oyster mushroom consumption produced significant reductions in fasting plasma glucose, postprandial glucose, total cholesterol, triglycerides, and blood pressure compared to baseline. No impairment of liver, kidney, or hematopoietic tissue function was observed. Khatun et al., Mymensingh Medical Journal, 2007.

A clinical study examined the hypoglycemic activity of culinary Pleurotus ostreatus and P. cystidiosus mushrooms in healthy volunteers and patients with type 2 diabetes on diet control. Both groups showed reductions in fasting blood glucose following mushroom consumption, with proposed mechanisms including alpha-glucosidase inhibition. Jayasuriya et al., Phytotherapy Research, 2015.

The GLP-1 connection

A distinct but related line of research has investigated the effect of oyster mushroom consumption on glucagon-like peptide-1 (GLP-1), the gut hormone that regulates insulin secretion, slows gastric emptying, and suppresses appetite. A 2025 randomized controlled trial published in the European Journal of Nutrition found that fortifying a single meal with oyster mushroom powder significantly increased GLP-1 response and reduced non-esterified fatty acid concentrations in adults with impaired glucose tolerance. GLP-1 is the hormone pathway targeted by a class of weight management medications, and the finding that a dietary intervention increases GLP-1 response through a food-based mechanism is clinically noteworthy.

A 2024 randomized parallel study enrolled 60 adults consuming either a Mediterranean diet with or without whole oyster mushrooms for eight weeks. The mushroom group showed significantly improved fasting serum glucose at the end of the intervention period compared to the control group (change from baseline: −2.9 ± 1.18 versus 0.6 ± 1.10 mg/dL; p = 0.034), while adopting the Mediterranean diet alone without mushrooms did not produce the same glucose effect. The authors concluded that including one serving per day of whole Pleurotus ostreatus improved fasting serum glucose in middle-aged and older adults classified as overweight or obese.

A randomized, double-blind, controlled crossover trial found that fortifying a single meal with beta-glucan-rich oyster mushroom powder significantly increased GLP-1 response and reduced non-esterified fatty acid concentrations in adults with impaired glucose tolerance compared to a control meal. The GLP-1 response was further found to depend on gut microbiota composition prior to the meal. Klümpen et al., European Journal of Nutrition, 2025.

A randomized parallel study of 60 adults consuming a Mediterranean diet with or without whole Agaricus bisporus and Pleurotus ostreatus mushrooms for eight weeks found that the mushroom group showed significantly improved fasting serum glucose compared to the control group (p = 0.034), while the dietary pattern alone did not produce the same effect. Uffelman et al., Journal of Nutrition, 2024.

What the evidence does and does not show

The body of clinical evidence on oyster mushrooms and blood glucose is larger and more consistent than is generally recognized. Eight clinical trials, a systematic review, a Mediterranean diet intervention study, and recent GLP-1 mechanism research all point in the same direction: oyster mushroom consumption is associated with measurable effects on glucose metabolism in humans across multiple study designs and populations.

What the evidence does not yet show is large-scale, randomized, double-blind trial data with standardized oyster mushroom preparations, clearly defined doses, and long-term follow-up across diverse patient populations. The 2020 Ellinger and Stehle systematic review explicitly noted that risk of bias was high or unclear in most of the included studies, and called for further rigorously designed trials. Some of the earliest studies lacked control groups. These are real methodological limitations that qualify the strength of the current evidence base.

The appropriate characterization of the current science is: consistent, mechanistically coherent, positive across all available human studies, and in need of larger and more rigorously designed trials before definitive clinical recommendations can be made.

This article reports on peer-reviewed scientific research. It is not intended to diagnose, treat, cure, or prevent any disease or medical condition, and does not constitute medical advice. Individuals managing diabetes or blood sugar conditions should consult their healthcare provider before making dietary changes.

Continue exploring the science

• The Natural Food That Works With Your Body's GLP-1

• Oyster Mushrooms and Healthy Cholesterol: The Lovastatin Evidence

• Why Eat Oyster Mushrooms? The Full Research Overview